2,1,3-苯并噁二唑-4-甲醇 | 175609-19-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶二唑类
• 中文名称: 2,1,3-苯并噁二唑-4-甲醇
• 英文名称: 4-hydroxymethylbenzofurazan
• 英文别名: 2,1,3-benzoxadiazole-4-yl-methanol；2,1,3-Benzoxadiazol-4-ylmethanol
• CAS: 175609-19-5
• 化学式: C₇H₆N₂O₂
• mdl: MFCD04115376
• 分子量: 150.137
• InChiKey: OKDMFOBEJCALFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险类别码：
  R36/37/38
• 海关编码：
  2934999090
• 安全说明：
  S26,S36/37/39
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Name:	2 1 3-Benzoxadiazol-4-ylmethanol Material Safety Data Sheet
Synonym:	None Known
CAS:	175609-19-5

Section 1 - Chemical Product MSDS Name:2 1 3-Benzoxadiazol-4-ylmethanol Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175609-19-5	2,1,3-Benzoxadiazol-4-ylmethanol	100	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: In case of contact, immediately flush eyes with plenty of water for at least 15 minutes. Get medical aid.
Skin:
In case of contact, flush skin with plenty of water. Remove contaminated clothing and shoes. Get medical aid if irritation develops and persists. Wash clothing before reuse.
Ingestion:
If swallowed, do not induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an unconscious person. Get medical aid.
Inhalation:
If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175609-19-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 71 - 73 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H6N2O2
Molecular Weight: 150.14

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175609-19-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,1,3-Benzoxadiazol-4-ylmethanol - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 175609-19-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175609-19-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175609-19-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,1,3-苯并噁二唑-4-甲醇 在 硫酰氟 、 potassium carbonate 、 二甲基亚砜 作用下， 生成 苯并二唑-4-甲醛
  参考文献：
  名称：

  SO2F2介导的无过渡金属一锅级联过程，用于将初级醇（RCH2OH）转化为腈（RCN）

  摘要：

  在不引入“额外碳原子”的情况下，开发了一种新的无过渡金属的单锅级联工艺，用于将醇直接转化为腈。该方案允许将容易获得，廉价和丰富的醇转化为高价值的腈。

  DOI：

  10.1002/ejoc.201900478
• 作为产物：
  描述：

  苯并二唑-4-甲醛 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 以82%的产率得到2,1,3-苯并噁二唑-4-甲醇
  参考文献：
  名称：

  Identification, synthesis and evaluation of substituted benzofurazans as inhibitors of CREB-mediated gene transcription

  摘要：

  Cyclic-AMP response-element binding protein (CREB) is a stimulus-activated transcription factor. Its transcription activity requires its binding with CREB-binding protein (CBP) after CREB is phosphorylated at Ser133. The domains involved for CREB-CBP interaction are kinase-inducible domain (KID) from CREB and KID-interacting domain (KIX) from CBP. Recent studies suggest that CREB is an attractive target for novel cancer therapeutics. To identify novel chemotypes as inhibitors of KIX-KID interaction, we screened the NCI-diversity set of compounds using a split renilla luciferase assay and identified 2-[(7-nitrobenzo[ c][1,2,5]oxadiazol-4-yl)thio] pyridine 1-oxide (compound 1, NSC228155) as a potent inhibitor of KIX-KID interaction. However, compound 1 was not particularly selective against CREB-mediated gene transcription in living HEK 293T cells. Further structure-activityrelationship studies identified 4-aniline substituted nitrobenzofurazans with improved selectivity. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.07.053

文献信息

• A Transition-Metal-Free One-Pot Cascade Process for Transformation of Primary Alcohols (RCH₂ OH) to Nitriles (RCN) Mediated by SO₂ F₂
  作者：Ying Jiang、Bing Sun、Wan-Yin Fang、Hua-Li Qin

  DOI：10.1002/ejoc.201900478

  日期：2019.6.2

  A new transition‐metal‐free one‐pot cascade process for the direct conversion of alcohols to nitriles was developed without introducing an “additional carbon atom”. This protocol allows transformations of readily available, inexpensive, and abundant alcohols to highly valuable nitriles.

  在不引入“额外碳原子”的情况下，开发了一种新的无过渡金属的单锅级联工艺，用于将醇直接转化为腈。该方案允许将容易获得，廉价和丰富的醇转化为高价值的腈。
• [EN] PROCESS FOR THE MANUFACTURE OF 2,1,3-BENZOXADIAZOLE-4-CARBOXALDEHYDE<br/>[FR] PROCEDE D'ELABORATION DE 2,1,3-BENZOXADIAZOLE-4-CARBOXALDEHYDE
  申请人：SHASUN CHEMICALS AND DRUGS LTD

  公开号：WO2005023787A1

  公开（公告）日：2005-03-17

  The present invention relates to an improved and novel method for the manufacture of 2,1,3-benzoxadiazole-4-carboxaldehyde an intermediate for the preparation of 4-(4-Benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl 1-methylethyl ester known as Isradipine. More particularly the present invention relates to the process for the manufacture 2,1,3-benzoxadiazole-4-carboxaldehyde from 2,1,3-benzoxadiazole-4-yl-methanol by oxidation using pyridinium chlorochromate (PCC) as oxidant.

  本发明涉及一种改进和新颖的方法，用于制备2,1,3-苯并氧二唑-4-甲醛，这是制备4-(4-苯并呋喃基)-1,4-二氢-2,6-二甲基-3,5-吡啶二甲酸甲基-1-甲基乙酯（即依拉地平）的中间体。更具体地，本发明涉及一种从2,1,3-苯并氧二唑-4-基-甲醇经过氧化反应制备2,1,3-苯并氧二唑-4-甲醛的方法，使用吡啶氯铬酸铵（PCC）作为氧化剂。
• Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
  申请人：Bristol-Myers Squibb Company

  公开号：EP1854798A2

  公开（公告）日：2007-11-14

  Fused cyclic compounds, method of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

  融合环状化合物、使用此类化合物治疗核荷尔蒙受体相关疾病（如癌症和免疫紊乱）的方法，以及含有此类化合物的药物组合物。
• Benzofurazanyl- and benzofuroxanyl-1,4-dihydropyridines: synthesis, structure and calcium entry blocker activity
  作者：AM Gasco、G Ermondi、R Fruttero、A Gasco

  DOI：10.1016/s0223-5234(96)80001-8

  日期：1996.1

  The synthesis, structural characterization and calcium blocking activity of a series of benzofurazanyl-1,4-dihydropyridines (18 and 19) and benzofuroxanyl analogues (20 and 21) are reported. H-1-NMR showed that all the benzofuroxan derivatives exist in solution as tautomeric mixtures. The predominant tautomeric form in solution of the derivative 20 (dimethyl 1,4-dihydro-2,6-dimethyl-4-(4-benzofuroxanyl)-3,5-pyridinedicarboxylate) is also the one preferred in the solid state as shown by X-ray analysis. The conformation in the solid state of the benzofurazanyl analogue is also reported. Calcium entry blocker activity of the dihydropyridine derivatives 18-21 has been evaluated in isolated rabbit basilar artery as relaxation of calcium-induced contractions in high K+-depolarizing solution. All the compounds displayed high potency. The activity of benzofurazan derivatives was not changed by the N-oxidation. The two most active compounds 18 and 20 were as potent as Nifedipine.
• US7470797B2
  申请人：——

  公开号：US7470797B2

  公开（公告）日：2008-12-30